1 Differential age-specific effects of LDL cholesterol and body mass index on the

- 2 risk of coronary heart disease.
- 3 Jun Xiao, M.D., Ph.D^{1,2}, Liangwan Chen, M.D., Ph.D^{1,2}, Weimin Ye, M.D., Ph.D^{3,4}*,
- 4 Wuqing Huang, M.D., Ph.D³*
- ¹ Department of Cardiovascular Surgery, Fujian Medical University Union Hospital,
- 6 Fuzhou, Fujian, China.
- 7 ² Fujian Provincial Clinical Research Center for Cardiovascular Diseases Heart Center
- 8 of Fujian Medical University, Fuzhou, Fujian, China.
- 9 ³ Department of Epidemiology and Health Statistics, School of Public Health, Fujian
- 10 Medical University, Fuzhou, Fujian, China.
- 11 ⁴ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
- 12 Stockholm, Sweden.
- 13 Short title: LDL cholesterol, BMI and coronary heart disease.
- 14 *Share the senior authorship.
- 15 Correspondence: Wuqing Huang and Weimin Ye
- 16 Fujian Medical University
- 17 No 1, Xue Yuan Road, University Town, 350108
- 18 Fuzhou City, Fujian Province, China.
- 19 Email: wuqing.huang@fjmu.edu.cn;ywm@fjmu.edu.cn
- 20 Telephone: +8617338896101
- 21 Word count: abstract(255), text(3349), figures(4),tables(4)
- 22 Abbreviations: BMI, body mass index; CHD, coronary heart disease; LDLc, low-

23	density lipoprotein cholesterol; MetS, metabolic syndrome; MI, myocardial infarction;
24	PERM, percentage of excess risk mediated; RCS, restricted cubic spline; RERI,
25	relative excess risk due to interaction.
26	Acknowledgments: This study has been performed using the UK Biobank Resource
27	under Application Number 84352. We thank the subjects and investigators who
28	contributed to the UK Biobank.
29	Competing interests: The authors declare no conflict of interest.
30	Funding Information: This work was supported by the Natural Science Foundation
31	of Fujian Province (grant no. 2022J01706) and the Start-up Fund for high-level talents
32	of Fujian Medical University (grant no.XRCZX2021026) to Dr. Wuqing Huang, and
33	by the Start-up Fund for high-level talents of Fujian Medical University (grant no.
34	XRCZX2017035 and XRCZX2020034) to Dr. Weimin Ye. The funder had no role in
35	study design, data collection and interpretation, or the decision to submit the work for
36	publication.
37	Author Contributors: All authors were responsible for the study concept and design.
38	WH and WY obtained funding. JX did the statistical analysis, JX and WH drafted the

39 manuscript, and all authors revised it for important intellectual content.

40 **Data Sharing Statement**

41 Data from the UK Biobank is available to researchers upon a data access application.

42 Clinical Perspective

43 What Is New?

- This study shows, for the first time, that there were differential age-specific 44 45 effects of LDLc and BMI on the risk of developing coronary heart disease (CHD), 46 in which the LDLc-CHD association diminished with increasing age while no 47 declining trend was found in BMI-CHD relationship. 48 The interaction and mediation between LDLc and BMI on the risk of coronary 49 heart disease were only present in young adults. What Are the Clinical Implications? 50 51 Future efforts are called to discriminate the age-different benefits from lipids 52 management or weight control on the primary prevention for CHD. 53 Findings from this study highlighted that lipids management at young age was 54 expected to have a much more favorable benefit in CHD prevention; and weight
- 55 control shouldn't be overlooked, especially for elderly adults, as lipid-lowering
- 56 therapy might not contribute to the reduction of obesity-related CHD.

57 Abstract

58	Background: Low-density lipoprotein cholesterol (LDLc) and body mass index (BMI)
59	are not always correlated and their relationship is probably dependent on age,
60	indicating differential age-specific effects of these two factors on health outcomes. We
61	thus aimed to discriminate the effects of LDLc and BMI on the risk of coronary heart
62	disease (CHD) across different age groups.
63	Methods: This is a prospective cohort study of 368,274 participants aged 38-73 years
64	and free of CHD at baseline. LDLc and BMI were measured at baseline, and incident
65	CHD was the main outcome. Cox proportional hazards model and restricted cubic
66	spline (RCS) regression were used to estimate hazard ratio (HR) and 95% confidence
67	interval (CI) of exposure on CHD.
68	Results: Similar relationships of LDLc and BMI with CHD risk were observed in
69	overall population but in differential age-specific patterns. Across the age groups of
70	<50, 50-54, 55-59, 60-64 and $>=$ 65 years, the LDLc-CHD association diminished
71	with the adjusted HRs decreasing from 1.35, 1.26, 1.19, 1.11 to 1.08; while no
72	declining trend was found in BMI-CHD relationship with the adjusted HRs of 1.15,
73	1.11, 1.12, 1.13 and 1.15, respectively. The interaction and mediation between LDLc
74	and BMI on CHD risk were only present at young-age groups. And the LDLc-CHD
75	but not BMI-CHD association was dependent on sex, metabolic syndrome and
76	lipid-lowering drugs use.

77 Conclusion: There were differential age-specific effects of LDLc and BMI on the risk78 of developing CHD, calling for future efforts to discriminate the age-different benefits

79 from lipids management or weight control on the primary prevention for CHD.

80 Introduction

Population aging leads to an increased incidence of coronary heart disease (CHD). 81 82 Low-density lipoprotein cholesterol (LDLc) and body mass index (BMI) are 83 well-established determinants of CHD, both of which are complex phenotypes and 84 shared lots of common risk factors. Besides, both obesity and high cholesterol have 85 been involved in "paradox" phenomenon, defined as higher cholesterol or BMI being 86 associated with an elevated incidence of diseases while paradoxically related to a reduced mortality ^{1,2}. Thus, it seems plausible to expect similar effects of these two 87 factors on diseases. Nevertheless, emerging evidence found that LDLc and BMI were 88 not always correlated, for example, findings from two large cross-sectional studies 89 90 found that the association between BMI and LDLc was completely lost in population 91 older than 60 years, indicating that the role of LDLc and BMI in diseases might not always stay in sync and probably varied by age³. A number of studies have 92 93 investigated the age-specific effect of LDLc on CHD but generated inconsistent 94 results, and the influence of age was poorly demonstrated on the association between BMI and CHD⁴⁻⁹. To date, there is insufficient data discriminating the independent 95 96 effect of LDLc and BMI on the risk CHD across the lifespan.

97 The high prevalence of hyperlipidemia and obesity, as well as the demographic 98 variation relevant to aging population, call for concerns to clarify the age-specific 99 health effects of LDLc and BMI so as to anticipate benefits that might be achieved via 100 LDLc reduction or weight control at different ages. Hence, in this study, we aimed to 101 explore how the effects of LDLc and BMI on the risk of developing CHD varied from

102	mid-life through late-life. Given of the prior evidence regarding the impact of sex and
103	metabolic disorders in the BMI-LDLc relationship and the known effect of
104	lipid-lowering treatment on CHD, we also performed stratified analyses to explore
105	whether the age-specific associations differ by sex, metabolic syndrome (MetS) and
106	lipid-lowering drug use ^{3, 10} .

107 Methods

108 Study design and population

This cohort study was conducted based on UK Biobank project, which recruited more than 500 000 residents aged 38–73 years in 22 assessment centers across the UK ¹¹. At the baseline visit between March 2006 and July 2010, participants completed online or/and verbal questionnaires and physical measurements, as well as provided biological sample. The North West Multi-Centre Research Ethics Committee has approved UK Biobank study (REC reference: 21/NW/0157) and all participants signed informed consent.

In this study, participants were excluded if they: (1) had a history of CHD before baseline visit, (2) had less than 180 days of follow-up, (3) had missing data of lipids or physical measurements. Finally, a total of 368,274 participants were included for

119 analysis (Supplementary Figure 1).

120 Assessment of exposure and covariates

Weight and height were measured at baseline and BMI was calculated as weight (kg) being divided by height (m) squared. Blood samples were collected at baseline and the levels of serum lipids were measured using the Beckman Coulter AU5800

124 Platform, in which LDLc was measured directly and analyzed via enzymatic selective protection method ^{12, 13}. To reduce systematic error, standardized procedures were 125 126 conducted for each sample following the protocol and Internal Quality Control (IQC) was performed for each assay, details of which have been described elsewhere ^{12, 13}. 127 128 Sociodemographic and lifestyle information were obtained by self-reported 129 questionnaires. Age was calculated as the difference between the date of birth and 130 baseline assessment. Ethnicity was dichotomized as British or not. Education was 131 recorded as six categories and unknown group. Socioeconomic status was measured by the Townsend deprivation index assigned at baseline ¹⁴. Smoking status was 132 133 categorized as never, former smoker, current smoker and unknown status; passive 134 smoking status was dichotomized as yes or not. Alcohol intake frequency was 135 categorized as daily, often (one to four times a week), seldom (one to three times a 136 month or special occasions only), never and unknown. Physical activity was assessed 137 using the International Physical Activity Questionnaire and recorded as summed metabolic equivalent (MET) minutes per week for all activity ^{15, 16}. Metabolic 138 139 disorders, including hypertension, hyperglycemia/diabetes, hypertriglyceridemia and 140 low high-density lipoprotein (HDL) cholesterol, were defined according to the IDF 141 definition by combining information from self-report medical conditions, medications 142 and biochemistry data at baseline (systolic blood pressure>=130 mmHg or diastolic 143 blood pressure>=85 mmHg; fasting plasma glucose >=5.6 mmol/l; triglycerides>=1.7 mmol/l; HDL cholesterol ≤ 1.03 mmol/l in men or ≤ 1.29 mmol/l in women)¹⁷. MetS 144 was defined as having central obesity (waist circumference >=90 cm in men or >=80145

146 cm in women) and two or more metabolic disorders mentioned above ¹⁷. Use of
147 lipid-lowering drugs was self-reported in touchscreen questionnaire or verbal
148 interview at baseline.

149 Assessment of outcomes

150 The main outcome was incident CHD and the secondary outcome was incident 151 myocardial infarction (MI). CHD was identified by using the International 152 Classification of Disease 10 of I20-I25 from category of "First occurrence" (Category 153 ID: 1712) with Field IDs of 131297, 131299, 131301, 131303, 131305 and 131307. 154 Myocardial infarction was identified by using Field ID of 42001 from category of 155 "Algorithmically-defined outcomes" (Category ID: 42). Fields in both "First 156 occurrence" and "Algorithmically-defined outcomes" categories were derived from self-reported medical conditions, primary health care, hospital admission data and 157 158 death registry data in the UK Biobank cohort.

159 Statistical analysis

Baseline characteristics are presented as frequency and percentage for categorical variables and as mean and standard deviation for continuous variables across different age groups (i.e., <50 years, 50-54 years, 55-59 years, 60-64 years, and >=65 years). Participants were followed up from the date of baseline assessment to the date of the outcome occurrence, the date of death, the date of loss-to-follow, or the censoring date (May 20, 2022), whichever occurred first.

We first explored the associations between LDLc, BMI and risk of CHD indifferent age groups. Restricted cubic spline (RCS) regression was first applied to

168	explore the non-linear relationship by including the exposure as a continuous variable,
169	in which we tried to perform models with different knots and found that there was
170	little change in the shape since four knots, thus RCS regression with four knots was
171	chosen as the main model ¹⁸ . Next, Cox proportional hazards model was used to
172	investigate the hazard ratio (HR) and 95% confidence interval (CI) between LDLc,
173	BMI and risk of CHD, in which, based on clinical relevance and previous literature,
174	we modelled LDLc per 1 mmol/L increment as follows: <2, 2-2.9, 3-3.9, 4-4.9, 5-5.9,
175	and ≥ 6 mmol/L; and modelled BMI per class increment using standard categories as
176	follows: underweight (<18.5 kg/m ²), healthy weight (18.5-24.9 kg/m ²), overweight
177	(25.0-29.9 kg/m ²), obesity class 1 (30.0-34.9 kg/m ²), obesity class 2 (35.0-39.9 kg/m ²),
178	and obesity class 3 (\geq 40 kg/m ²) ^{5, 19} . Given of the potential impact of competing risk
179	from death, Fine-Gray competing risk model was further performed to examine the
180	association by defining death as a competing event. Stratified analyses were also
181	performed by sex, MetS or lipid-lowering drugs use across different age groups, and
182	heterogeneity between strata was tested by including a product term of the
183	stratification factor and exposure in the model. The models were first adjusted for age
184	at baseline and sex, then in multivariable models additionally for ethnicity, education,
185	smoking, passive smoking, alcohol intake frequency, physical activity, Townsend
186	deprivation index, metabolic disorders, lipid lowering drugs, and body mass index or
187	LDLc.

188 We further evaluated the age-specific mediation and interaction between LDLc189 and BMI on CHD. Mediation analysis was performed to explore the mediated role of

190	LDLc between BMI and CHD, or the role of BMI between LDLc and CHD, by using
191	the percentage of excess risk mediated (PERM), which was calculated by using the
192	$formula \ of \ (HR_{(confounders \ adjusted)} \ - \ HR_{(confounders \ and \ mediator \ adjusted)})/ \ (HR_{(confounders \ adjusted)} \ - \ HR_{(confounders \ adjusted)})/ \ (HR_{(confounders \ adjusted)})/ \ (HR_{(confounde$
193	1). Interaction between LDLc and BMI on CHD were assessed in both additive scale
194	and multiplicative scale ²⁰ . Addictive interaction was measured by relative excess risk
195	due to interaction (RERI), calculated as $HR_{(increased LDLc & increased BMI)}$ - $HR_{(increased BMI)}$
196	$_{alone)}$ – HR $_{(increased LDLc alone)}$ + 1, in which LDLc and BMI was dichotomized as
197	increased or not according to the cut-off value of 3.4 mmol/L and 25 $\mbox{kg/m}^2$
198	respectively, and then the population was divided into four groups for analysis (i.e.,
199	neither LDLc nor BMI increased, LDLc increased alone, BMI increased alone and
200	both increased). Multiplicative interaction was identified by the p value of
201	product-term of LDLc and BMI in the multivariable model.

All analyses were performed in SAS 9.4 or R 4.1.2 and *P*-value of <0.05 was considered as of statistical significance.

204 **Results**

As shown in **Table 1**, a total of 368,274 participants were included in the analyses, consisting of 202,853 (55.1%) females and 165,421 (44.9%) males. The mean age of study population was 57 years, the mean level of LDLc was 3.6 mmol/L and the mean BMI was 27.3 kg/m². After a mean of 12 years of follow-up, 26,947 participants developed CHD with the incidence rate of 5.86 per 1000 person-years, and the incidence rates of CHD continuously increased with increasing age. There were 84717, 56544, 65680, 87263, 74070 participants across age groups of <50 years,

212 50-54 years, 55-59 years, 60-64 years, and >=65 years, and the distribution of 213 sociodemographic characteristics, lifestyle, history of metabolic disorders and 214 lipid-lowering drug use were significantly different across age groups. 215 **Supplementary Figure 2** shows that participants with LDLc of 3-3.9 mmol/L or BMI 216 of 25-29.5 kg/m² accounted for the highest proportion across all age groups.

217 As shown in Figure 1 and Supplementary Figure 3, RCS regression found near 218 linear relationship between LDLc, BMI and CHD risk, especially when the level of 219 LDLc or BMI was above 3 mmol/L or 25 kg/m². Stratified analyses by age groups 220 observed that the association of LDLc but not BMI with CHD almost diminished with 221 the increasing age (Figure 2). Cox proportional hazards model found similar elevated 222 risk of CHD for the overall population per 1 mmol/L increment in LDLc 223 (multivariable adjusted HR: 1.16, 95% CI: 1.14-1.18) and per class increment in BMI 224 (multivariable adjusted HR: 1.14, 95% CI: 1.12-1.16) (Table 2). Consistent with 225 findings from RCS regression, stratified analyses in Cox proportional hazards model 226 showed that across the age groups of <50, 50-54, 55-59, 60-64 and >=65 years, the 227 positive association between LDLc and CHD declined along the increasing age with 228 the multivariable adjusted HRs decreasing from 1.35, 1.26, 1.19, 1.11 to 1.08 229 $(P_{\text{heterogeneity}} < 0.001)$; however, although there was a significant heterogeneity in 230 BMI-CHD associations across age groups, no decling trend was observed with 231 increasing age, and the multivariable adjusted HRs of which were 1.15, 1.11, 1.12, 232 1.13 and 1.15, respectively (Figure 3 and Table 2). Fine-Gray competing risk model 233 showed similar results, suggesting a small role of the competing risk in the observed

associations (Supplementary Table 1). Supplementary Table 2 shows the results for MI; similarly, the positive association of LDLc with the risk of MI also declined across the increasing age ($P_{heterogeneity} < 0.001$) while the relationship between BMI and MI was independent of age ($P_{heterogeneity}=0.128$). Although the effect on MI related to per 1 mmol/L higher in LDLc was always greater than that associated with per class higher in BMI across all age groups, the difference in the association of LDLc and BMI with MI was attenuating with increasing age.

241 In Figure 4 and Supplementary Table 3, stratified analyses by sex found a 242 significantly stronger LDLc-CHD association (P heterogeneity for overall population: 243 <0.001) and a slightly insignificantly stronger BMI-CHD association (P heterogeneity 244 for overall population: 0.405) in males than females across all age groups; irrespective 245 of sex, the LDLc-CHD association declined with increasing age while the BMI-CHD 246 association kept stable. In Figure 2 and Supplementary Table 4, stratified analyses 247 by MetS observed a stronger association between LDLc and CHD among individuals 248 without MetS than those with, across all age groups despite without statistical 249 significance in some age groups (P heterogeneity for overall population: <0.001), 250 while no significant heterogeneity was found in BMI-CHD association between 251 individuals with and without MetS in most age groups except the age group of 252 younger than 50 years (P heterogeneity for overall population: 0.346); regardless of 253 MetS, diminished trend was found in LDLc-CHD but not BMI-CHD association with 254 increasing age. In Figure 2 and Supplementary Table 5, stratified analyses by 255 lipid-lowering drug use showed significant heterogeneity in LDLc-CHD association

between lipid-lowering drug users and non-users, specifically among adults younger
than 55 years old (P heterogeneity=0.001); besides, the LDLc-CHD association
declined with increasing age in non-users but kept stable in lipid-lowering drug users,
while no obvious trend was observed for BMI-CHD association regardless of
lipid-lowering drug use or not.

261 Mediation analysis found that LDLc played a mediated role in BMI-CHD 262 association at young ages with the PERM of 11.76% and 8.33% in the age group of 263 <50 years and 50-54 years respectively; the mediated effect of BMI in LDLc-CHD 264 association was only observed in the age group of <50 years with the PERM of 2.78% 265 (Table 3). Interaction analysis showed a greater positive addictive interaction between 266 BMI and LDLc in younger adults than older ones although no significant 267 multiplicative interaction found throughout all ages; the effect of higher LDLc alone 268 or both higher BMI and LDLc on CHD risk declined with increasing age while no 269 significant trend was found for the effect of higher BMI alone on CHD (Table 4).

270 Discussion

This prospective cohort study found similar independent effects of LDLc and BMI on CHD risk in overall population, while the age-specific associations with CHD risk showed significant different patterns between LDLc and BMI. The LDLc-CHD association declined with increasing age while the BMI-CHD relationship was independent of age. The strongest negative effect of high LDLc on CHD was found in young adults without using lipid-lowering drugs, and the interactive effect between LDLc and lipid-lowering drug use on CHD risk was only observed in adults younger

than 55 years. Besides, the interaction and mediation between LDLc and BMI on CHD were only present in young adults. These findings highlighted that lipids management at young age was expected to have a much more favorable benefit in CHD prevention; and weight control shouldn't be overlooked, especially for elderly adults, as lipid-lowering therapy might not contribute to the reduction of obesity-related CHD.

Hypercholesterolemia and obesity share some common risk factors and pathophysiologic mechanisms, both of non-negligible importance in the onset of CHD. Although previous literature has found observational and genetic associations between BMI and LDLc, growing evidence suggested that the correlation seemed to be varied by metabolic status linked to aging or metabolic disorders, indicating that the health effect of BMI and LDLc might not always stay consistent^{3, 10, 21, 22}.

Age has been reported to play a role in the association of BMI or LDLc with 290 health outcomes ^{1, 4-8}. Despite the causal relationship between LDLc and the risk of 291 292 CHD, the impact of LDLc or the benefit of lipid-lowering therapy on the occurrence of CHD is being challenged in older population^{4-8, 23-25}. Some studies have observed 293 294 that the positive association of LDLc with incident CHD attenuated or even 295 disappeared in older adults, while a recent contemporary cohort argued that 296 individuals aged 70-100 years with higher LDLc had the highest absolute risk of 297 atherosclerotic cardiovascular disease as compared to other age groups, suggesting the 298 importance of LDLc-lowering treatment for prevention in extremely-elderly population⁴⁻⁸. The net benefit of statins use on primary prevention of atherosclerotic 299

300 cardiovascular events was also controversial and guidelines regarding the role of statins remained equivocal in older adults²³⁻²⁵. The "obesity paradox" phenomenon 301 302 has been proposed for decades with respect to the lower mortality in obese adults in 303 older patients ¹. Nevertheless, the age-related effect of obesity in the incidence of 304 diseases was rarely clarified, and previous studies found a declining trend in the effect 305 of higher BMI on the occurrence of some diseases, such as dementia, while a cohort 306 study of population aged >60 years found that obesity was independently associated with elevated incidence of CHD in older population, at least to age 84^{9,26}. There is a 307 308 dearth of data on discrimination of the independent effect of LDLc and BMI on health 309 outcomes across age groups. In the current study, we found similar relationships for 310 both LDLc and BMI with the risk of developing CHD but differential age-specific 311 effects between LDLc and BMI. The excess risk on CHD from higher LDLc 312 attenuated with increasing age while the relationship between BMI and the incidence 313 of CHD kept stable across all age groups, resulting in a greater excess risk associated 314 with per mmol/L higher in LDLc in young adults but a higher excess risk related to 315 per class increase in BMI in adults older than 60 years. Despite declined strength of 316 the LDLc-CHD association in elderly people, the negative health effect of higher 317 LDLc stayed statistically significant. These findings casted doubt on suggestions 318 about guideline revision given of the "obesity paradox" or "cholesterol paradox" 319 phenomenon at older ages but called for future efforts to discriminate the 320 age-different benefits from lipids management or weight control on the primary 321 prevention for CHD.

322	Some studies have investigated the mediated role of LDLc between BMI and
323	CHD, for example, a large pooled analysis found the excess risk of CHD per unit of
324	BMI can be largely explained by metabolic mediators whereas cholesterol explained
325	only additional 5% excess risk; another population-based study found that LDLc
326	explained the excess risk of CHD with 22% excess risk from the observational obesity
327	and 8% excess risk from genetically-determined obesity ^{22, 27} . In this study, we
328	extended the knowledge in light of the age-different mediation or interaction between
329	LDLc and BMI on the risk of CHD, and found that the mediated effect of LDLc or
330	BMI between BMI or LDLc and CHD risk was only present in young adults, so did
331	the interaction effect, indicating a greater benefit of lipids management or weight
332	control on preventing CHD at young ages.

333 Difference in the sex- or MetS- specific effects was further observed between 334 LDLc and BMI on CHD risk in this study. A prior cohort study in Korean population 335 demonstrated sex-specific association of MetS (an obesity-driven complex disorder) 336 and LDLc with the incidence of cardiovascular and cerebrovascular disease (CCVD), 337 in which MetS alone was linked with a higher risk of CCVD regardless of sex while 338 the impact of higher LDLc alone on CCVD was more pronounced in men than in women ²⁸. Consistently, the current study found that the association of BMI with 339 340 CHD risk was independent of sex but the effect of high LDLc on CHD was significantly greater in men than in women across all age groups. MetS also seemed 341 342 to play a role in the LDLc-CHD but not BMI-CHD relationship; the effect of higher 343 LDLc was stronger among people without MetS than those with, which called for

more studies in light of the underlying reasons. In addition, stratified analyses by lipid-lowering drug use observed the highest excess risk of CHD related to high LDLc in youngest adults without using lipid-lowering drugs and the absent heterogeneity in the effect of LDLc on CHD between users and non-users in older adults, further suggesting that lipids management should start at earlier ages for the primary prevention of CHD.

350 This study had some strengths. First, this study extended the knowledge 351 regarding the differential age-specific effects of LDLc and BMI on the risk of 352 developing CHD. Second, the large sample size allowed us to explore the associations 353 across age groups per 5-year interval with sufficient statistical power. Third, 354 information of the outcome was obtained by combining several sources to minimize 355 the misclassification of outcome. Fourth, several statistical methods were applied to 356 estimate the associations, contributing to examine the robustness of the results. The 357 major limitation of this study was that the age of this study population ranged from 38 358 to 73, thus not allowing us to explore the relationship in extreme elderly individuals. 359 Besides, most participants in UK Biobank are European, thus findings should be 360 interpreted cautiously in terms of generalization.

In conclusion, this study found differential age-specific effects between LDLc and BMI on the risk of developing CHD, calling for future efforts to discriminate the age-different benefits from lipids management or weight control on the primary prevention for CHD.

365

18

366	Referen	ces:

367	1.	Wang	S	and	Ren	J.	Obesity	Paradox	in	Aging:	From	Prevalence	to
368	Pat	hophysi	olo	gy. Pr	ogress	s in	cardiovas	cular dise	ases	. 2018;61	:182-18	39.	

- 369 2. Orkaby AR. The Highs and Lows of Cholesterol: A Paradox of Healthy Aging?
- *Journal of the American Geriatrics Society*. 2020;68:236-237.
- 371 3. Laclaustra M, Lopez-Garcia E, Civeira F, Garcia-Esquinas E, Graciani A,
- 372 Guallar-Castillon P, Banegas JR and Rodriguez-Artalejo F. LDL Cholesterol Rises
- 373 With BMI Only in Lean Individuals: Cross-sectional U.S. and Spanish Representative
- 374 Data. *Diabetes care*. 2018;41:2195-2201.
- 375 4. Jung HN, Kim MJ, Kim HS, Lee WJ, Min SH, Kim YJ and Jung CH.
- 376 Age-Related Associations of Low-Density Lipoprotein Cholesterol and
 377 Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Cohort
 378 Study. *Journal of the American Heart Association*. 2022;11:e024637.
- 5. Mortensen MB and Nordestgaard BG. Elevated LDL cholesterol and increased
- risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals
- aged 70-100 years: a contemporary primary prevention cohort. Lancet (London,
- *England*). 2020;396:1644-1652.

383 6. Nanna MG, Navar AM, Wojdyla D and Peterson ED. The Association Between

- 384 Low-Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular
- 385 Disease in Older Adults: Results From the National Institutes of Health Pooled
- 386 Cohorts. *Journal of the American Geriatrics Society*. 2019;67:2560-2567.
- 387 7. Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G

388	and Yusuf S. Age and Cardiovascular Risk Attributable to Apolipoprotein B,
389	Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.
390	Journal of the American Heart Association. 2016;5.
391	8. Iversen A, Jensen JS, Scharling H and Schnohr P. Hypercholesterolaemia and risk
392	of coronary heart disease in the elderly: impact of age: the Copenhagen City Heart
393	Study. European journal of internal medicine. 2009;20:139-44.
394	9. Bowman K, Delgado J, Henley WE, Masoli JA, Kos K, Brayne C, Thokala P,
395	Lafortune L, Kuchel GA, Ble A and Melzer D. Obesity in Older People With and
396	Without Conditions Associated With Weight Loss: Follow-up of 955,000 Primary
397	Care Patients. The journals of gerontology Series A, Biological sciences and medical
398	sciences. 2017;72:203-209.
399	10. Li H, Ma J, Zheng D, Li X, Guo X, Wang J and Su P. Sex differences in the
400	non-linear association between BMI and LDL cholesterol in middle-aged and older

- 401 adults: findings from two nationally representative surveys in China. *Lipids Health*402 *Dis*. 2021;20:162.
- 403 11. Palmer LJ. UK Biobank: bank on it. *Lancet (London, England)*.
 404 2007;369:1980-1982.
- 405 12. Fry D, Almond R, Moffat S, Gordon M, Singh P. Companion Document to
- 406 Accompany Serum Biomarker Data [Internet]. UK Biobank Biomarker Project. 2019
- 407[cited2020Feb4].Availablefrom:
- 408 <u>https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf</u>.
- 409 13. Elliott P and Peakman TC. The UK Biobank sample handling and storage

- 410 protocol for the collection, processing and archiving of human blood and urine.
- 411 *International journal of epidemiology*. 2008;37:234-44.
- 412 14. Jarman B, Townsend P and Carstairs V. Deprivation indices. BMJ (Clinical
- 413 *research ed*). 1991;303:523.
- 414 15. The IPAQ Group. IPAQ scoring protocol International Physical Activity
- 415 Questionnaire. <u>https://sites.google.com/site/theipaq/scoring-protocol</u>.
- 416 16. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ,
- 417 O'Brien WL, Bassett DR, Jr., Schmitz KH, Emplaincourt PO, Jacobs DR, Jr. and Leon
- 418 AS. Compendium of physical activities: an update of activity codes and MET
- 419 intensities. *Medicine and science in sports and exercise*. 2000;32:S498-504.
- 420 17. Ford ES. Prevalence of the metabolic syndrome defined by the International
- 421 Diabetes Federation among adults in the U.S. *Diabetes care*. 2005;28:2745-9.
- 422 18. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to
- 423 categorical analysis. *Epidemiology*. 1995;6:356-65.
- 424 19. Flegal KM, Kit BK, Orpana H and Graubard BI. Association of all-cause
- 425 mortality with overweight and obesity using standard body mass index categories: a
- 426 systematic review and meta-analysis. *Jama*. 2013;309:71-82.
- 427 20. Li R and Chambless L. Test for additive interaction in proportional hazards
 428 models. *Ann Epidemiol.* 2007;17:227-36.
- 429 21. Reeder BA, Angel A, Ledoux M, Rabkin SW, Young TK and Sweet LE. Obesity
- 430 and its relation to cardiovascular disease risk factors in Canadian adults. Canadian
- 431 Heart Health Surveys Research Group. CMAJ : Canadian Medical Association

432 *journal = journal de l'Association medicale canadienne.* 1992;146:2009-19.

433	22. Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A and Nordestgaard
434	BG. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as
435	mediators from obesity to ischemic heart disease. Circulation research.
436	2015;116:665-73.
437	23. Orkaby AR, Gaziano JM, Djousse L and Driver JA. Statins for Primary
438	Prevention of Cardiovascular Events and Mortality in Older Men. Journal of the
439	American Geriatrics Society. 2017;65:2362-2368.
440	24. Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, Galloway A, Vassy
441	JL, Forman DE, Gaziano JM, Gagnon DR, Wilson PWF, Cho K and Djousse L.
442	Association of Statin Use With All-Cause and Cardiovascular Mortality in US
443	Veterans 75 Years and Older. Jama. 2020;324:68-78.
444	25. Hawley CE, Roefaro J, Forman DE and Orkaby AR. Statins for Primary

- 445 Prevention in Those Aged 70 Years and Older: A Critical Review of Recent
 446 Cholesterol Guidelines. *Drugs & aging*. 2019;36:687-699.
- 447 26. Karlsson IK, Lehto K, Gatz M, Reynolds CA and Dahl Aslan AK. Age-dependent
- 448 effects of body mass index across the adult life span on the risk of dementia: a cohort
- study with a genetic approach. *BMC medicine*. 2020;18:131.
- 450 27. Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB and Danaei G.
- 451 Metabolic mediators of the effects of body-mass index, overweight, and obesity on
- 452 coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with
- 453 1.8 million participants. *Lancet (London, England)*. 2014;383:970-83.

454	28.	Kim	SY.	Go	TH.	Lee J	H.	Moon	JS.	Kang	DR.	Bae	SJ.	Kim	SE.	Lee	SJ.	Cho	DH.
-	-		,		,					C	, ,				,				,

- 455 Park YJ, Youn YJ, Kim JY and Ahn SG. Differential association of metabolic
- 456 syndrome and low-density lipoprotein cholesterol with incident cardiovascular disease
- 457 according to sex among Koreans: a national population-based study. European
- 458 *journal of preventive cardiology*. 2022;28:2021-2029.
- 459

460 Figure legends:

461	Figure 1. Association of LDL cholesterol or body mass index with risk of coronary
462	heart disease via restricted cubic spline regression (four knots). *Adjusted for age, sex,
463	ethnicity, education, smoking, passive smoking, alcohol intake frequency, physical
464	activity, Townsend deprivation index, metabolic disorders, lipid lowering drugs and
465	body mass index or LDL cholesterol.
466	Figure 2. Association of LDL cholesterol or body mass index with risk of coronary
467	heart disease across age groups via restricted cubic spline regression (four knots).
468	*Adjusted for age, sex, ethnicity, education, smoking, passive smoking, alcohol intake
469	frequency, physical activity, Townsend deprivation index, metabolic disorders, lipid
470	lowering drugs and body mass index or LDL cholesterol.
471	Figure 3: Association of LDL cholesterol or body mass index with risk of coronary
472	heart disease across increasing age via Cox proportional hazards model. *Adjusted for
473	age, sex, ethnicity, education, smoking, passive smoking, alcohol intake frequency,
474	physical activity, Townsend deprivation index, metabolic disorders, lipid lowering
475	drugs and body mass index or LDL cholesterol.

476 Figure 4: Stratified analyses for the association of LDL cholesterol or body mass 477 index with risk of coronary heart disease across age groups via Cox proportional 478 hazards model. *Adjusted for age, sex, ethnicity, education, smoking, passive 479 smoking, alcohol intake frequency, physical activity, Townsend deprivation index, 480 metabolic disorders, lipid lowering drugs and body mass index or LDL cholesterol.

481

24

Variables	Study population	<50 years	50-54 years	55-59 years	60-64 years	>=65 years	Р
v ariables	(N=368274)	(N=84717)	(N=56544)	(N=65680)	(N=87263)	(N=74070)	value
Age	56.7±8.1	45.2±2.6	52.1±1.4	57.1±1.4	62±1.4	67.1±1.6	< 0.001
LDL Cholesterol, mmol/L	$3.6{\pm}0.8$	$3.4{\pm}0.8$	3.6±0.8	3.7 ± 0.8	3.7±0.9	3.6±0.9	< 0.001
Body mass index, kg/m2	27.3±4.7	26.9±4.9	27.3±4.9	27.4±4.8	27.4±4.6	27.4±4.3	< 0.001
Townsend deprivation index	-1.4±3	-0.9 ± 3.2	-1.2±3.1	-1.4±3	-1.6±2.9	-1.6±2.9	< 0.001
Summed MET, min/week	2668±2718	2660.7±2769.7	2569.4±2719.2	2538.7±2691.5	2706.4 ± 2693.2	2829.1±2696.5	< 0.001
Sex							< 0.001
Female	202853(55.1)	45922(54.2)	31962(56.5)	37048(56.4)	48783(55.9)	39138(52.8)	
Male	165421(44.9)	38795(45.8)	24582(43.5)	28632(43.6)	38480(44.1)	34932(47.2)	
Ethnicity							< 0.001
British	324425(88.1)	69723(82.3)	48715(86.2)	58283(88.7)	79975(91.6)	67729(91.4)	
Others	43849(11.9)	14994(17.7)	7829(13.8)	7397(11.3)	7288(8.4)	6341(8.6)	
Education							< 0.001
College or University degree	121308(32.9)	33372(39.4)	20958(37.1)	23554(35.9)	25834(29.6)	17590(23.7)	
A levels/AS levels or equivalent	41605(11.3)	11586(13.7)	7516(13.3)	7785(11.9)	8639(9.9)	6079(8.2)	
O levels/GCSEs or equivalent	79500(21.6)	19824(23.4)	11953(21.1)	13166(20)	18968(21.7)	15589(21)	
CSEs or equivalent	20785(5.6)	8704(10.3)	4737(8.4)	3660(5.6)	2453(2.8)	1231(1.7)	
NVQ or equivalent	23660(6.4)	4151(4.9)	3627(6.4)	4642(7.1)	6419(7.4)	4821(6.5)	
Other professional qualifications	18785(5.1)	2118(2.5)	2107(3.7)	3430(5.2)	5681(6.5)	5449(7.4)	
Unknown	62631(17)	4962(5.9)	5646(10)	9443(14.4)	19269(22.1)	23311(31.5)	
Smoking							< 0.001
Never	203911(55.4)	51766(61.1)	33515(59.3)	36140(55)	45370(52)	37120(50.1)	
Previous	124601(33.8)	20813(24.6)	16121(28.5)	22578(34.4)	33955(38.9)	31134(42)	
Current	37998(10.3)	11785(13.9)	6702(11.9)	6688(10.2)	7497(8.6)	5326(7.2)	

Unknown	1764(0.5)	353(0.4)	206(0.4)	274(0.4)	441(0.5)	490(0.7)	
Passive smoking							< 0.001
No	322151(87.5)	71988(85)	48725(86.2)	57536(87.6)	77708(89.1)	66194(89.4)	
Yes	46123(12.5)	12729(15)	7819(13.8)	8144(12.4)	9555(10.9)	7876(10.6)	
Alcohol intake frequency							< 0.001
Daily	75829(20.6)	12803(15.1)	10445(18.5)	14162(21.6)	20596(23.6)	17823(24.1)	
Often	180605(49)	44256(52.2)	29248(51.7)	32753(49.9)	41565(47.6)	32783(44.3)	
Seldom	82719(22.5)	20912(24.7)	12682(22.4)	13973(21.3)	18454(21.1)	16698(22.5)	
Never	28341(7.7)	6510(7.7)	4041(7.1)	4667(7.1)	6511(7.5)	6612(8.9)	
Unknown	780(0.2)	236(0.3)	128(0.2)	125(0.2)	137(0.2)	154(0.2)	
Metabolic disorder							
Hypertension	237905(64.6)	38136(10.4)	32477(8.8)	42877(65.3)	64124(73.5)	60291(81.4)	< 0.001
Hyperglycemia/diabetes	59777(16.2)	9170(2.5)	7578(2.1)	10562(16.1)	16207(18.6)	16260(22)	< 0.001
Hypertriglyceridemia	145646(39.5)	28048(7.6)	21298(5.8)	26693(40.6)	37539(43)	32068(43.3)	< 0.001
Low HDL Cholesterol	74743(20.3)	20459(5.6)	11467(3.1)	12254(18.7)	16380(18.8)	14183(19.1)	< 0.001
Use of lipid lowering drugs	51240(13.9)	3082(0.8)	4360(1.2)	8032(12.2)	16337(18.7)	19429(26.2)	< 0.001

	Number of	Number of	Follow up years	IR, per 1000 person years	LDL cholesterol		Body mass index		
Age	individuals				Age and sex	Multivariable	Age and sex	Multivariable	
		outcomes			adjusted	adjusted ^a	adjusted	adjusted ^a	
Overall	368274	26947	4595322	5.86	1.04(1.02,1.05)	1.16(1.14,1.18)	1.31(1.29,1.32)	1.14(1.12,1.16)	
<50	84717	2524	1099075	2.30	1.38(1.32,1.44)	1.35(1.29,1.41)	1.46(1.40,1.51)	1.15(1.10,1.20)	
50-54	56544	2746	723131	3.80	1.18(1.13,1.23)	1.26(1.20,1.31)	1.33(1.28,1.38)	1.11(1.07,1.16)	
55-59	65680	4361	827492	5.27	1.06(1.03,1.10)	1.19(1.15,1.24)	1.31(1.28,1.35)	1.12(1.08,1.16)	
60-64	87263	7928	1071790	7.40	0.99(0.96,1.01)	1.11(1.08,1.14)	1.28(1.25,1.31)	1.13(1.10,1.16)	
>=65	74070	9388	873834	10.74	0.94(0.92,0.96)	1.08(1.05,1.11)	1.27(1.24,1.30)	1.15(1.12,1.17)	
P heterogene	eity				< 0.001	< 0.001	< 0.001	< 0.001	

Table 2. Association of LDL cholesterol or body mass index with risk of coronary heart disease across age groups.

^a Adjusted for age, sex, birth country, education, smoking, passive smoking, alcohol intake frequency, physical activity, Townsend deprivation index, metabolic disorders, lipid lowering drugs and body mass index or LDL cholesterol.

Table 3. Mediation of LDL cholesterol or body mass index between body mass index or LDL cholesterol and risk of coronary heart disease across age groups.

		LDL cholestero	l	Body mass index			
Age	Confounders adjusted ^a	Confounders and BMI adjusted ^b	The percentage of excess risk mediated	Confounders adjusted ^a	Confounders and LDLc adjusted ^b	The percentage of excess risk mediated	
Overall	1.16(1.15,1.18)	1.16(1.14,1.18)	0%	1.14(1.13,1.16)	1.14(1.12,1.16)	0%	
<50	1.36(1.30,1.42)	1.35(1.29,1.41)	2.78%	1.17(1.12,1.21)	1.15(1.10,1.20)	11.76%	
50-54	1.26(1.20,1.32)	1.26(1.20,1.31)	0%	1.12(1.08,1.17)	1.11(1.07,1.16)	8.33%	
55-59	1.19(1.15,1.24)	1.19(1.15,1.24)	0%	1.12(1.09,1.16)	1.12(1.08,1.16)	0%	
60-64	1.11(1.08,1.14)	1.11(1.08,1.14)	0%	1.13(1.10,1.16)	1.13(1.10,1.16)	0%	
>=65	1.07(1.05,1.10)	1.08(1.05,1.11)	-	1.15(1.12,1.17)	1.15(1.12,1.17)	0%	

^a Adjusted for age, sex, ethnicity, education, smoking, passive smoking, alcohol intake frequency, physical activity, Townsend deprivation index, metabolic disorders, lipid lowering drugs;

^b Adjusted for age, sex, ethnicity, education, smoking, passive smoking, alcohol intake frequency, physical activity, Townsend deprivation index, metabolic disorders, lipid lowering drugs and body mass index or LDL cholesterol.

		Adjusted	Deletive evenes visle	P for		
Age	None	Increased body mass index	Increased LDL cholesterol	Both increased	oth increased of interaction	
Overall	Ref	1.19(1.14,1.25)	1.27(1.20,1.34)	1.49(1.43,1.56)	0.03	0.688
<50	Ref	1.31(1.12,1.53)	1.57(1.31,1.87)	2.06(1.78,2.39)	0.18	0.981
50-54	Ref	1.02(0.88,1.19)	1.24(1.05,1.46)	1.51(1.31,1.74)	0.25	0.067
55-59	Ref	1.10(0.97,1.24)	1.24(1.09,1.42)	1.42(1.27,1.60)	0.08	0.559
60-64	Ref	1.17(1.07,1.27)	1.17(1.06,1.29)	1.41(1.29,1.53)	0.07	0.563
>=65	Ref	1.23(1.14,1.32)	1.17(1.07,1.28)	1.31(1.21,1.42)	-0.09	0.070

Table 4. Interaction between LDL cholesterol and body mass index on the risk of coronary heart disease across age groups.

^a Adjusted for age, sex, ethnicity, education, smoking, passive smoking, alcohol intake frequency, physical activity, Townsend deprivation index, metabolic disorders and lipid lowering drugs.







